Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate

This study is the first clinical trial using sodium oxybate for the treatment of REM sleep behavior disorder (RBD). Sodium oxybate is a drug approved by FDA for the treatment of narcolepsy which has been used "off label" to treat patients with severe RBD. This drug has shown to be effective and well tolerated in patients with RBD (Shneerson, 2009; Liebenthal, 2016; Moghadam, 2017).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Jazz Pharmaceuticals

Stanford Investigator(s):


  • Drug: Sodium Oxybate
  • Other: Placebo


Phase 4


Inclusion Criteria:

   - 40-85 years old

   - With or without Parkinson's disease

   - Experiencing RBD episodes on average at least 2x/week or 8x/month

   - Able to report RBD episodes themselves or via a partner witness

Exclusion Criteria:

   - History of falls during ambulation in the last 6 months despite adequate neurologic

   - Requirement of an ambulatory device at home

   - Inadequately treated symptomatic orthostatic hypotension

   - BMI > 35

   - Untreated or uncontrolled OSA (4%AHI>15)

   - Cognitive impairment resulting in inability to comply with treatment instructions

   - Pregnancy

Ages Eligible for Study

40 Years - 85 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Emmanuel During